ADAlexandre Descamps

Alexandre Descamps

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandre Descamps has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Évaluation de la sévérité et de l'impact associés aux infections respiratoires virales (dont grippe et Covid-19) chez l'adulte hospitalisé en France

    by Alexandre Descamps

    Les virus respiratoires sont des agents étiologiques fréquents des infections respiratoires aiguës documentées chez l'adulte. Il existe un nombre important d'objectifs de recherche en milieu hospitalier afin de mieux comprendre leur sévérité dans différentes populations et disposer de données épidémiologiques actualisées. Si la grippe a été largement étudiée chez l'adulte hospitalisé, la morbi-mortalité due à d'autres virus et en particulier au virus respiratoire syncytial (VRS) était sous-estimée jusqu'à récemment. En dehors des épidémies saisonnières d'origine virale, l'émergence du SARS-CoV-2 a considérablement modifié notre perception de l'impact des virus respiratoires et posait d'importantes questions en matière de priorité de recherche et d'organisation des soins. En l'absence de thérapeutique et de vaccin au stade précoce de la pandémie, une meilleure compréhension du sur-risque associé aux populations vulnérables était nécessaire afin de proposer des interventions adaptées. Ensuite, un des défis pour les structures de soins hospitalières comme ambulatoires était de proposer une prise en charge adaptée aux patients atteints de formes pauci-/asymptomatiques selon leur évolution clinique et leur risque de développer une forme grave. Pour cela, trois axes d'étude ont été développés. La première partie des travaux de thèse avait pour objectif de comparer le devenir des adultes hospitalisés pour une infection respiratoire aiguë sévère à partir des données d'un réseau de surveillance hospitalier pour la grippe et les autres virus respiratoires. Les résultats de l'étude suggèrent que l'infection à VRS peut entraîner des complications intra-hospitalières plus importantes que la grippe, en particulier une augmentation de la survenue de complications respiratoires, d'admission en unité de soins intensifs et de recours aux supports ventilatoires invasifs. Deuxièmement, dans le contexte de l'épidémie à SARS-CoV-2, le second travail avait pour objectif d'évaluer la sévérité et l'évolution intra-hospitalière des patients avec une pathologie psychiatrique hospitalisés pour COVID-19. Cette étude a été réalisée à partir de la base de données nationale hospitalière du PMSI. Dans cette cohorte rétrospective, nous avons cherché à déterminer si les caractéristiques socio-démographiques et médicales, la durée de séjour, l'admission en réanimation et la mortalité intra-hospitalière différaient entre les patients avec et sans un diagnostic de maladie mentale grave. Nous rapportons une association positive entre la présence de troubles mentaux préexistants et la mortalité intra-hospitalière à 30 jours, indépendamment de la présence de facteurs de risque individuels, potentiels ou établis, de développer une forme grave de COVID-19. Des disparités dans l'admission et la durée de séjour en soins critiques ont également été rapportées. Ces résultats indiquent l'importance d'une prise en charge adéquate et d'interventions ciblées, y compris la priorité à la vaccination, chez les patients les plus à risque souffrant de troubles mentaux sévères. La troisième partie des travaux avait pour objectif de contribuer à l'évaluation à 18 mois des patients inclus dans le dispositif Covidom (plateforme de télésuivi des patients à domicile atteints de COVID-19). L'évaluation comprenait une analyse descriptive de l'utilisation de la plateforme ainsi qu'une analyse des coûts d'hospitalisation des patients pris en charge dans les établissements de l'AP-HP. La plateforme de télésurveillance a contribué à absorber la demande de soins principalement pendant les premiers mois de la pandémie. Les résultats rapportent que le dispositif était sûr pour la surveillance à domicile et la détection des aggravations. De plus, les coûts d'hospitalisation pour aggravation paraissaient inférieurs à ceux des patients non pris en charge par le dispositif, bien que cette différence ne soit pas suffisante pour que l'outil soit neutre en termes de coûts.

  • Eating disorders in children under 4 years of age with autism spectrum disorder: Description and determinants

    by Clémentine Socie, Alexandre Descamps, Béatrice Thouvenin, Catherine du Fraysseix Peigné, Véronique Abadie, Lisa Ouss


  • Open Access

    Influenza and pneumococcal vaccine coverage among adults hospitalized with acute respiratory infection in France: A prospective cohort study

    by Simon Rolland, Lb. Luong Nguyen, A. Descamps, F. Galtier, X. Duval, P. Vanhems, F. Lainé, P. Tattevin, R. Bauer, O. Launay


  • Open Access

    Effectiveness and Medicoeconomic Evaluation of Home Monitoring of Patients With Mild COVID-19: Covidom Cohort Study

    by Luc Jaulmes, Youri Yordanov, Alexandre Descamps, Isabelle Durand-Zaleski, Aurélien Dinh, Patrick Jourdain, Agnès Dechartres

    Background: Covidom was a telemonitoring solution for home monitoring of patients with mild to moderate COVID-19, deployed in March 2020 in the Greater Paris area in France to alleviate the burden on the health care system. The Covidom solution included a free mobile application with daily monitoring questionnaires and a regional control center to quickly handle patient alerts, including dispatching emergency medical services when necessary. Objective: This study aimed to provide an overall evaluation of the Covidom solution 18 months after its inception in terms of effectiveness, safety, and cost. Methods: Our primary outcome was to measure effectiveness using the number of handled alerts, response escalation, and patient-reported medical contacts outside of Covidom. Then, we analyzed the safety of Covidom by assessing its ability to detect clinical worsening, defined as hospitalization or death, and the number of patients with clinical worsening without any preceding alert. We evaluated the cost of Covidom and compared the cost of hospitalization for Covidom and non-Covidom patients with mild COVID-19 cases seen in the emergency departments of the largest network of hospitals in the Greater Paris area (Assistance Publique-Hôpitaux de Paris). Finally, we reported on user satisfaction. Results: Of the 60,073 patients monitored by Covidom, the regional control center handled 285,496 alerts and dispatched emergency medical services 518 times. Of the 13,204 respondents who responded to either of the follow-up questionnaires, 65.8% (n=8690) reported having sought medical care outside the Covidom solution during their monitoring period. Of the 947 patients who experienced clinical worsening while adhering to daily monitoring, only 35 (3.7%) did not previously trigger alerts (35 were hospitalized, including 1 who died). The average cost of Covidom was €54 (US $1=€0.8614) per patient, and the cost of hospitalization for COVID-19 worsening was significantly lower in Covidom than in non-Covidom patients with mild COVID-19 cases seen in the emergency departments of Assistance Publique-Hôpitaux de Paris. The patients who responded to the satisfaction questionnaire had a median rating of 9 (out of 10) for the likelihood of recommending Covidom. Conclusions: Covidom may have contributed to alleviating the pressure on the health care system in the initial months of the pandemic, although its impact was lower than anticipated, with a substantial number of patients having consulted outside of Covidom. Covidom seems to be safe for home monitoring of patients with mild to moderate COVID-19.


  • Open Access

    Effectiveness and Medicoeconomic Evaluation of Home Monitoring of Patients With Mild COVID-19: Covidom Cohort Study (Preprint)

    by Luc Jaulmes, Youri Yordanov, Alexandre Descamps, Isabelle Durand-Zaleski, Aurélien Dinh, Patrick Jourdain, Agnès Dechartres

    BACKGROUND Covidom was a telemonitoring solution for home monitoring of patients with mild to moderate COVID-19, deployed in March 2020 in the Greater Paris area in France to alleviate the burden on the health care system. The Covidom solution included a free mobile application with daily monitoring questionnaires and a regional control center to quickly handle patient alerts, including dispatching emergency medical services when necessary. OBJECTIVE This study aimed to provide an overall evaluation of the Covidom solution 18 months after its inception in terms of effectiveness, safety, and cost. METHODS Our primary outcome was to measure effectiveness using the number of handled alerts, response escalation, and patient-reported medical contacts outside of Covidom. Then, we analyzed the safety of Covidom by assessing its ability to detect clinical worsening, defined as hospitalization or death, and the number of patients with clinical worsening without any preceding alert. We evaluated the cost of Covidom and compared the cost of hospitalization for Covidom and non-Covidom patients with mild COVID-19 cases seen in the emergency departments of the largest network of hospitals in the Greater Paris area (Assistance Publique-Hôpitaux de Paris). Finally, we reported on user satisfaction. RESULTS Of the 60,073 patients monitored by Covidom, the regional control center handled 285,496 alerts and dispatched emergency medical services 518 times. Of the 13,204 respondents who responded to either of the follow-up questionnaires, 65.8% (n=8690) reported having sought medical care outside the Covidom solution during their monitoring period. Of the 947 patients who experienced clinical worsening while adhering to daily monitoring, only 35 (3.7%) did not previously trigger alerts (35 were hospitalized, including 1 who died). The average cost of Covidom was €54 (US $1=€0.8614) per patient, and the cost of hospitalization for COVID-19 worsening was significantly lower in Covidom than in non-Covidom patients with mild COVID-19 cases seen in the emergency departments of Assistance Publique-Hôpitaux de Paris. The patients who responded to the satisfaction questionnaire had a median rating of 9 (out of 10) for the likelihood of recommending Covidom. CONCLUSIONS Covidom may have contributed to alleviating the pressure on the health care system in the initial months of the pandemic, although its impact was lower than anticipated, with a substantial number of patients having consulted outside of Covidom. Covidom seems to be safe for home monitoring of patients with mild to moderate COVID-19.

  • Association between mental disorders and COVID-19 outcomes among inpatients in France: A retrospective nationwide population-based study

    by Alexandre Descamps, Jérôme Frenkiel, Kevin Zarca, Charles Laidi, Ophélia Godin, Odile Launay, Marion Leboyer, Isabelle Durand-Zaleski


  • Open Access

    A cross-sectional study on infectious health risks regarding freshwater sports practice in Brittany, France

    by Fanny Velardo, Hanifa Bouziri, Lucie Adélaïde, Emma Oliosi, Maylis Layan, Alexandre Descamps, Delphine Berthod, Alan R. Patlán-Hernández, Martine Ledrans, Mathilde Pivette, et al.

    Freshwater sports expose practitioners to pathogens in the water environment and may result in infection. In French Brittany, these infections are particularly worrying, especially since 2016 with an increase in the incidence of leptospirosis reaching 1 case per 100,000 inhabitants, which represents the highest incidence observed since 1920. We aimed to estimate the prevalence of infectious diseases related to freshwater sports practice and to identify the factors associated with these infections among freshwater sports licensees in Brittany, France. From March 18, 2019, to May 8, 2019, we interviewed freshwater sports licensees (online study) and club presidents and instructors (phone study) in Brittany. Licensee participants were 18 years old or more and practiced at least one freshwater sport in one of the 79 Brittany clubs. We used logistic regression models to study the association between our variables of interest and potential risk factors. In total, 551 licensees (20.3% of the total number of licensees) and 38 clubs (48.1%) were surveyed. Among the licensees, 29 (5.3%) reported being diagnosed with leptospirosis, of which 12 (41.3%) occurred in the last 5 years. The most reported symptoms were skin irritation/itchy skin (24.3%) and 39 individuals (7.1%) reported at least one hospitalization in their lifetime for a disease related to freshwater sports. The occurrence of leptospirosis was negatively associated with boarding from a pontoon (odds ratio (OR)=0.20, 95% confidence interval (95% CI) 0.06–0.56), practicing for less than 4 years (OR=0.17, 95% CI 0.04–0.56) compared to more than 10 years, and the occurrence of leptospirosis was positively associated with taking a soapy shower after practice (OR=4.38, 95% CI 1.90–10.51). Eskimo roll was positively associated with the occurrence of otitis and conjunctivitis (OR=3.22, 95% CI 1.82–6.03), and skin irritation/itchy skin (OR=1.66, 95% CI 0.99–2.84). Otitis, conjunctivitis, and skin irritation/itchy skin are the most commonly reported freshwater sport-related diseases in French Brittany. Despite a good level of knowledge of prevention measures, their implementation by licensees and clubs remains low. Further studies are needed to identify practices associated with infectious risk in freshwater sports.


  • In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017–2019: an observational study

    by Alexandre Descamps, Nezha Lenzi, Florence Galtier, Fabrice Lainé, Zineb Lesieur, Philippe Vanhems, Sélilah Amour, Anne-Sophie L'HOnneur, Nadhira Fidouh, Vincent Foulongne, et al.

    Objectives: The purpose of this study was to describe the clinical characteristics and in-hospital and post-discharge outcomes of respiratory syncytial virus (RSV) infection among adults hospitalised with influenza-like illness (ILI) and compared against patients admitted for influenza.Methods: Adults hospitalised with ILI were prospectively included from five French university hospitals over two consecutive winter seasons (2017/2018 and 2018/2019). RSV and influenza virus were detected by multiplex reverse transcription PCR on nasopharyngeal swabs. RSV-positive patients were compared to RSV-negative and influenza-positive hospitalised patients. Poisson regression models were used to estimate the adjusted prevalence ratio (aPR) associated with in-hospital and post-discharge outcomes between RSV and influenza infections. The in-hospital outcome was a composite of the occurrence of at least one complication, length of stay ≥7 days, intensive care unit admission, use of mechanical ventilation and in-hospital death. Post-discharge outcome included 30- and 90-day all-cause mortality and 90-day readmission rates.Results: Overall, 1428 hospitalised adults with ILI were included. RSV was detected in 8% (114 of 1428) and influenza virus in 31% (437 of 1428). Patients hospitalised with RSV were older than those with influenza (mean age 73.0versus68.8 years, p=0.015) with a higher frequency of chronic respiratory or cardiac disease (52%versus39%, p=0.012, and 52%versus41%, p=0.039, respectively) and longer hospitalisation duration (median stay 8versus6 days, pversus66%, p<0.001). In-hospital composite outcome was poorer in RSV patients (aPR 1.5, 95% CI 1.1–2.1) than in those hospitalised with influenza. No difference was observed for the post-discharge composite outcome (aPR 1.1, 95% CI 0.8–1.6).Conclusion: RSV infection results in serious respiratory illness, with worse in-hospital outcomes than influenza and with similar midterm post-discharge outcomes.


  • Open Access

    Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe – Results from the DRIVE EU study platform

    by Anke L. Stuurman, Jorne Biccler, Antonio Carmona, Alexandre Descamps, Javier Díez-Domingo, Cintia Muñoz Quiles, Hanna Nohynek, Caterina Rizzo, Margarita Riera-Montes


  • Open Access

    Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project

    by Antonio Carmona, Cintia Muñoz-Quiles, Anke Stuurman, Alexandre Descamps, Ainara Mira-Iglesias, Laurence Torcel-Pagnon, Javier Díez-Domingo

    The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to work with public health institutes to set up a joint IVE study platform. The COVID-19 pandemic reached Europe in February 2020 and overlapped with the 2019/2020 influenza season only in the last weeks. However, several elements of the DRIVE study network were impacted. The pandemic specifically affected the study sites’ routines and the subsequent assessment of the 2019/20 influenza season. Moreover, the current social distancing measures and lockdown policies across Europe are expected to also limit the circulation of influenza for the 2020/21 season, and therefore the impact of COVID-19 will be higher than in the season 2019/20. Consequently, DRIVE has planned to adapt its study platform to the COVID-19 challenge, encompassing several COVID-19 particularities in the study procedures, data collection and IVE analysis for the 2020/21 season. DRIVE will study the feasibility of implementing these COVID-19 components and establish the foundations of future COVID-19 vaccine effectiveness studies.